Hyperviscosity syndrome
Peer reviewed by Dr Hannah Gronow, MBACPLast updated by Dr Laurence KnottLast updated 3 Jul 2016
Meets Patient’s editorial guidelines
- DownloadDownload
- Share
- Language
- Discussion
- Ask Patient
- Audio Version
- Add to preferred sources on Google
Content notice
This page hasn’t been reviewed recently, so some information or external links may have changed.
Medical Professionals
Professional Reference articles are designed for health professionals to use. They are written by UK doctors and based on research evidence, UK and European Guidelines. You may find one of our health articles more useful.
Hyperviscosity refers to any state in which there is increased viscosity of the blood. Increased serum viscosity usually results from increased circulating serum immunoglobulins (eg, macroglobulinaemia, multiple myeloma) and can also result from increased cellular blood components (eg, red or white blood cells) in hyperproliferative states - eg, leukaemias, polycythaemia and thrombocythaemia.1
Epidemiology
The precise incidence of hyperviscosity syndrome is not known, as it may occur in a large number of conditions.
Hyperviscosity may occur at any age but the aetiology of that seen in infants is different from that seen in adults.
Conditions in which hyperviscosity may occur
Hyperviscosity occurs as a result of a raised haematocrit or due to increased levels of circulating plasma components. Many conditions may produce this state, including:2
Waldenström's macroglobulinaemia (most common cause).
Multiple myeloma.
Leukaemia (both acute and chronic).
Connective tissue disorders - eg, rheumatoid arthritis.
Retinoic acid therapy.
Cryoglobulinaemia.
Chronic hypoxia.
Paraneoplastic syndromes (hyperviscosity results from the large amounts of circulating immunoglobulins, cryoglobulins, paraproteins or antibodies, or due to an excessive increase in blood cells).
In infants, hyperviscosity may occur as a result of the polycythaemia which develops in response to intrauterine hypoxia or hypoxia during delivery.3
Presentation
Increased viscosity and reduced blood flow may result in a variety of clinical manifestations, including:
Central nervous system: lethargy, headache, nystagmus, deafness, convulsions.
Visual: papilloedema, fundal haemorrhages, dilation of the retinal vessels, loss of vision.4
Cardiovascular system: hypertension, heart failure.
Haematological: dilutional anaemia, abnormal bleeding (eg, bruising, mucosal bleeds, rectal bleeding, menorrhagia), thrombosis, leukocyte dysfunction (sepsis), crossmatch difficulties.
Renal: renal failure, proximal renal tubular acidosis.
Investigations
Plasma viscosity - increased.
FBC and differential cell count.
Blood film may show rouleaux formation.
Platelet count.
Clotting screen.
Other investigations to determine the underlying cause include bone marrow aspiration, urine electrophoresis, auto-antibody levels.
Management
Non-drug
Patients with a hyperviscosity syndrome should be advised that this may recur; they should be advised to look for signs of bleeding or infection.
Some conditions producing hyperviscosity may be helped by regular venesection - eg, polycythaemia rubra vera.
Unfortunately, repeated procedures may lead to iron deficiency, resulting in microcytic erythrocytes, which induce higher viscosity than normocytic erythrocytes. This may increase the risk for veno-occlusive events.5
Infants may be treated using partial exchange transfusion.
In adult patients, plasmapheresis to remove excess numbers of cells or circulating complexes remains the treatment of choice.61-2 procedures are advised for the treatment of hyperviscosity syndrome in Waldenström's macroglobulinaemia. In patients who are drug-resistant this may be indicated as long-term management.1
Drugs1
The underlying cause of the hyperviscosity syndrome may be treated with chemotherapy where appropriate. Rituximab is a commonly used agent.
Complications
Complications may occur as a result of bleeding, thrombosis or sepsis and may result in neurological deficit, heart failure and renal failure.
Prognosis
The overall prognosis for any patient will depend on the underlying condition and severity of any complications of hyperviscosity.
Patient picks for Haematology

Professional
Myalgic encephalomyelitis
What is myalgic encephalomyelitis. Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management; NICE guideline (October 2021) 61829 : NICE NG206 Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management Myalgic encephalomyelitis (ME), known more commonly as chronic fatigue.
by Dr Philippa Vincent, MRCGP

Professional
Down's syndrome
Background Children with Down's syndrome have multiple malformations, medical conditions and cognitive impairment because of the presence of extra genetic material from chromosome 21. Children with Down's syndrome often function more effectively in social situations than would be predicted on the basis of their cognit... Bull MJ; Health.
by Dr Hayley Willacy, FRCGP

Professional
Herpes zoster oticus
What is Ramsay Hunt syndrome. There are three separate neurological Ramsay Hunt syndromes. Their only connection is James Ramsay Hunt who identified them all. Only the first one will be covered in this leaflet. Ramsay Hunt syndrome (herpes zoster oticus or auricular herpes zoster) - described here. Ramsay Hunt cerebellar syndrome (dyssynergia.
by Dr Toni Hazell, FRCGP

Professional
Irritable bowel syndrome
What is irritable bowel syndrome. Irritable bowel syndrome (IBS) is a relapsing bowel disorder in which abdominal pain Abdominal pain is associated with defecation or a change in bowel habit. Irritable bowel syndrome: a global perspective; World Gastroenterology Organisation Global Guideline, April 2009 26609 : WGO World Gastroenterology.
by Dr Rachel Hudson, MRCGP

Professional
Horner's syndrome
Synonym: Bernard-Horner syndrome (commonly used in France); oculosympathetic paresis What is Horner's syndrome. Horner's syndrome is a rare condition that results from disruption of the sympathetic nerves supplying the eye. There is the triad of: Partial ptosis (upper eyelid drooping). Miosis (pupillary constriction) leading to anisocoria.
by Dr Toni Hazell, FRCGP

Professional
Vertebrobasilar insufficiency
Synonyms: vertebrobasilar stroke, vertebrobasilar insufficiency Occlusion or impairment of the vertebrobasilar blood supply affects the medulla, cerebellum, pons, midbrain, thalamus and occipital cortex. ...a number of clinical syndromes and is caused primarily by atherosclerosisPract Neurol. 2024 Jun 14:pn-2024-004160. doi:.
by Dr Doug McKechnie, MRCGP
Exclusive updates for healthcare professionals
Stay informed with the latest clinical updates, professional insights, and evidence-based guidance. The Patient Pro newsletter curates essential content for healthcare professionals—delivered straight to your inbox.
By subscribing you accept our Privacy Policy. You can unsubscribe at any time. We never sell your data.
Further reading and references
- Kundu S, Dey A, Sengupta A; Hyperviscosity syndrome with pulmonary involvement. J Indian Med Assoc. 2003 Sep;101(9):552-3.
- Ehrly A; Therapeutic Hemorheology, 2012.
- Stone MJ, Bogen SA; Evidence-based focused review of management of hyperviscosity syndrome. Blood. 2012 Mar 8;119(10):2205-8. doi: 10.1182/blood-2011-04-347690. Epub 2011 Dec 6.
- Rampling MW; Hyperviscosity as a complication in a variety of disorders. Semin Thromb Hemost. 2003 Oct;29(5):459-65.
- Rosenkrantz TS; Polycythemia and hyperviscosity in the newborn. Semin Thromb Hemost. 2003 Oct;29(5):515-27.
- Rajagopal R, Apte RS; Seeing through thick and through thin: Retinal manifestations of thrombophilic and hyperviscosity syndromes. Surv Ophthalmol. 2016 Mar-Apr;61(2):236-47. doi: 10.1016/j.survophthal.2015.10.006. Epub 2015 Oct 29.
- DeFilippis AP, Law K, Curtin S, et al; Blood is thicker than water: the management of hyperviscosity in adults with cyanotic heart disease. Cardiol Rev. 2007 Jan-Feb;15(1):31-4.
- Zarkovic M, Kwaan HC; Correction of hyperviscosity by apheresis. Semin Thromb Hemost. 2003 Oct;29(5):535-42.
About the reviewerView full bio

Dr Hannah Gronow, MBACP
General Practitioner
MB, ChB, MBACP
Hannah qualified as a GP in 1997. She joined EMIS (Patient) as a peer reviewer in August 2006.
More in haematology
- Acquired immune deficiency syndrome
- Antiplatelet drugs
- Blood products for transfusion
- Bone marrow and bone marrow failure
- Bruton's agammaglobulinaemia
- Burkitt's lymphoma
- Fluid overload
- Folate deficiency
- Glucose-6-phosphate dehydrogenase deficiency
- Grey platelet syndrome
- Haemodilution
- Haemolytic uraemic syndrome
- Haemophilia B
- Hodgkin's lymphoma
- Osler-Weber-Rendu syndrome
- Paraproteinaemia
- Pernicious anaemia and B12 deficiency
- Plasma autoantibodies
- Protein S deficiency
- Thalassaemia


